重组Anti-ERCC8抗体[EPR9237]
Anti-ERCC8 antibody [EPR9237]
- 20ul selling size
- RabMAb
- Recombinant
- KO Validated
- 了解详情
Be the first to review this product! Submit a review
|
(16 Publications)
Rabbit Recombinant Monoclonal ERCC8 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 16 publications.
查看别名
CKN1, CSA, ERCC8, DNA excision repair protein ERCC-8, Cockayne syndrome WD repeat protein CSA
- IP
Lab
Immunoprecipitation - Anti-ERCC8 antibody [EPR9237] (AB137033)
Purified ab137033 at 1/80 dilution (2μg) immunoprecipitating ERCC8 in HeLa whole cell lysate.
Lane 1 (input) : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10μg
Lane 2 (+) : ab137033 + HeLa whole cell lysate.
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab137033 in HeLa whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/5000 dilution) was used for Western blotting.
Blocking Buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM/TBST.
Observed band size : 44 kDa
All lanes:
Immunoprecipitation - Anti-ERCC8 antibody [EPR9237] (ab137033)
Predicted band size: 44 kDa
false
- WB
Unknown
Western blot - Anti-ERCC8 antibody [EPR9237] (AB137033)
Lane 1 : Wild-type HAP1 cell lysate (20 μg)
Lane 2 : ERCC8 knockout HAP1 cell lysate (20 μg)
Lane 3 : HeLa cell lysate (20 μg)
Lane 4 : Molt-4 cell lysate (20 μg)
Lanes 1 - 4 : Merged signal (red and green). Green - ab137033 observed at 44 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab137033 was shown to recognize ERCC8 when ERCC8 knockout samples were used, along with additional cross-reactive bands. Wild-type and ERCC8 knockout samples were subjected to SDS-PAGE. ab137033 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/2000 respectively, and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
All lanes:
Western blot - Anti-ERCC8 antibody [EPR9237] (ab137033)
Predicted band size: 44 kDa
false
- WB
Unknown
Western blot - Anti-ERCC8 antibody [EPR9237] (AB137033)
All lanes:
Western blot - Anti-ERCC8 antibody [EPR9237] (ab137033) at 1/1000 dilution
Lane 1:
MOLT-4 (Human lymphoblastic leukemia T lymphoblast) whole cell lysate at 15 µg
Lane 2:
293T (Human embryonic kidney epithelial cell) whole cell lysate at 15 µg
Lane 3:
HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 15 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/5000 dilution
Predicted band size: 44 kDa
false
不同偶联物与剂型 (1)
-
Anti-ERCC8 antibody [EPR9237] - BSA and Azide free
反应性数据
产品详情
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
性能和储存信息
形式
纯化工艺
存储溶液
运输条件
推荐的短期储存时间
推荐的短期储存条件
推荐的长期储存条件
分装信息
储存信息
补充信息
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
ERCC8 forms a part of the CSA complex which includes other proteins involved in the TC-NER pathway. The CSA complex targets the repair machinery to the site of transcription-blocking lesions. Identifying these lesions is critical to resuming normal transcription processes. The CSA protein therefore actively contributes to maintaining genomic stability by facilitating the correction of transcription-coupled DNA damage.
Pathways
ERCC8 participates directly in the nucleotide excision repair (NER) pathway specifically in its transcription-coupled repair subprocess. This pathway is integral to correcting helix-distorting DNA lesions that impede transcription. ERCC8 interacts closely with the Cockayne syndrome B (CSB) protein and RNA polymerase II during the repair process. This collaboration is important in modulating the restart of transcription post-repair.
产品实验方案
- Visit the General protocols
- Visit the Troubleshooting
靶点信息
文献 (16)
Recent publications for all applications. Explore the full list and refine your search
Cell death and differentiation : PubMed40374849
2025
Applications
Unspecified application
Species
Unspecified reactive species
Nucleic acids research 53: PubMed40219966
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in oncology 14:1476100 PubMed39582530
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 15:7089 PubMed39154022
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cell reports methods 4:100674 PubMed38176411
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nucleic acids research 51:6238-6245 PubMed37144462
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cells 11: PubMed36231052
2022
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 13:974 PubMed35190564
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cell 180:1228-1244.e24 PubMed32142649
2020
Applications
Unspecified application
Species
Unspecified reactive species
Nucleic acids research 48:2473-2485 PubMed31970402
2020
Applications
Unspecified application
Species
Unspecified reactive species
Abcam Product Promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com